Centauri Therapeutics Limited
PrivateLast Round
Series A
Extension
Feb 24, 2026
Total Funding Raised
$60.79M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Centauri Therapeutics Limited is a biotechnology company that develops novel immunotherapies for infectious diseases and oncology using its proprietary Alphamer platform technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Centauri Therapeutics Limited Comparables
Compare Centauri Therapeutics Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Clarametyx Biosciences | 79% | |
| Infex Therapeutics | 77% | |
| Aurobac Therapeutics | 76% |
Centauri Therapeutics Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 24, 2026 | ||||
| Grant | Jul 29, 2025 | ||||
| Grant | Nov 25, 2024 | ||||
| Grant | Feb 22, 2022 | ||||
| Series A | Jan 26, 2022 | ||||
Grant | Jan 7, 2020 |
Centauri Therapeutics Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series A Extension |
| Boehringer Ingelheim | Series A Extension, Series A |
| PACE (Pathways to Antimicrobial Clinical Efficacy) | Grant |
| CARB-X | Series A Extension, Grant |
| Innovate UK | Grant |
| Medicines Discovery Catapult | Grant |
| Novo Holdings | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 24, 2026
$8.1M round led by AMR Action Fund.
- Jul 29, 2025
$5.1M grant from CARB-X
Centauri Therapeutics Limited Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Centauri Therapeutics Limited's valuation, stock price, and market status.
Is Centauri Therapeutics Limited a public or private company?
Centauri Therapeutics Limited is a private company.
What is the current stock price of Centauri Therapeutics Limited?
Centauri Therapeutics Limited is a private company with no public stock price. No recent secondary market data is available.
How much is Centauri Therapeutics Limited worth (valuation)?
Valuation information for Centauri Therapeutics Limited is not publicly available.
Can I buy Centauri Therapeutics Limited stock?
Centauri Therapeutics Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Centauri Therapeutics Limited's last funding round?
Centauri Therapeutics Limited's most recent funding round was Series A on February 24, 2026.
Who are the main investors in Centauri Therapeutics Limited?
Key investors in Centauri Therapeutics Limited include AMR Action Fund, PACE (Pathways to Antimicrobial Clinical Efficacy), CARB-X, Innovate UK.
Will Centauri Therapeutics Limited IPO soon?
No public IPO plans have been announced for Centauri Therapeutics Limited.
How can I track Centauri Therapeutics Limited secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Centauri Therapeutics Limited's secondary market activity and sign up for updates.